On June 30, 2022, Novartis announced that it acquired Kedalion Therapeutics and its AcuStream technology, an innovative device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye. Wilson Sonsini Goodrich & Rosati advised Kedalion on the transaction.
Kedalion is a clinical-stage, venture-funded ophthalmic drug company based in Menlo Park, California. In November 2021, Kedalion Therapeutics announced the completion of its Series B financing led by Novartis, which included an exclusive option to acquire the company and its AcuStream technology.
The Wilson Sonsini team that advised Kedalion on the transaction includes:
Corporate/M&A
Ken Clark
Michael Coke
Ethan Lutske
Kenji Strait
IP/Technology Transactions
Lowell Segal
Miruna Predescu
Tony Nguyen
Employment Law
Rebecca Stuart
Briza Sanchez
Employee Benefits and Compensation
Scott McCall
Michael Klippert
Jason Chan
FDA/Regulatory
David Hoffmeister
Eva Yin
For more information, please see Novartis’ press release.